Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses. A follow-up of three patients.
Fruehauf
Stefan
S
Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany; stefan_fruehauf@med.uni-heidelberg.de
Buss
Eike C
EC
Tropaly
Julian
J
Kreipe
H H
HH
Ho
A D
AD
D018952:Antigens, CD34 / Q000097:blood; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002066:Busulfan / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D036102:Peripheral Blood Stem Cell Transplantation; D055728:Primary Myelofibrosis / Q000628:therapy*; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous
D018952:Antigens, CD34; D018906:Antineoplastic Agents, Alkylating; C018404:treosulfan; D002066:Busulfan